3-[(2,4-dichlorophenoxy)phen-4-yl]propionic acid | 881402-46-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[(2,4-dichlorophenoxy)phen-4-yl]propionic acid
• 英文别名: 3-(4-(2,4-Dichlorophenoxy)phenyl)propanoic acid；3-[4-(2,4-dichlorophenoxy)phenyl]propanoic acid
• CAS: 881402-46-6
• 化学式: C₁₅H₁₂Cl₂O₃
• 分子量: 311.164
• InChiKey: FMPYGTZFTZZLBV-UHFFFAOYSA-N

物化性质

• 沸点：
  429.2±45.0 °C(Predicted)
• 密度：
  1.365±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,4-二氯氟苯 在 palladium on carbon 、 水 、 氢气 、 sodium hydride 、 caesium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[(2,4-dichlorophenoxy)phen-4-yl]propionic acid
  参考文献：
  名称：

  3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists

  摘要：

  The design, synthesis, and structure-activity relationship (SAR) for a series of beta-substituted 3-(4-aryloxyaryl) propanoic acid GPR40 agonists is described. Systematic replacement of the pendant aryloxy group led to identification of potent GPR40 agonists. In order to identify candidates suitable for in vivo validation of the target, serum shifted potency and pharmacokinetic properties were determined for several compounds. Finally, further profiling of compound 7 is presented, including demonstration of enhanced glucose tolerance in an in vivo mouse model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.114

文献信息

• NOVEL HETEROCYCLIC COMPOUNDS
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20160257701A1

  公开（公告）日：2016-09-08

  The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及一种新的GPR 40激动剂，其通式为（I），它们的互变异构体，立体异构体，药学上可接受的盐，包含它们的制药组合物，制备它们的方法，这些化合物在医学上的使用以及其制备中涉及的中间体。
• NOVEL HERBICIDE RESISTANCE GENES
  申请人：Wright Terry R.

  公开号：US20110124503A1

  公开（公告）日：2011-05-26

  The subject invention provides novel plants that are not only resistant to 2,4-D and other phenoxy auxin herbicides, but also to aryloxyphenoxypropionate herbicides. Heretofore, there was no expectation or suggestion that a plant with both of these advantageous properties could be produced by the introduction of a single gene. The subject invention also includes plants that produce one or more enzymes of the subject invention alone or “stacked” together with another herbicide resistance gene, preferably a glyphosate resistance gene, so as to provide broader and more robust weed control, increased treatment flexibility, and improved herbicide resistance management options. More specifically, preferred enzymes and genes for use according to the subject invention are referred to herein as AAD (aryloxyalkanoate dioxygenase) genes and proteins. No α-ketoglutarate-dependent dioxygenase enzyme has previously been reported to have the ability to degrade herbicides of different chemical classes and modes of action. This highly novel discovery is the basis of significant herbicide tolerant crop trait opportunities as well as development of selectable marker technology. The subject invention also includes related methods of controlling weeds. The subject invention enables novel combinations of herbicides to be used in new ways. Furthermore, the subject invention provides novel methods of preventing the formation of, and controlling, weeds that are resistant (or naturally more tolerant) to one or more herbicides such as glyphosate.
• 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists
  作者：Shawn P. Walsh、Alexandra Severino、Changyou Zhou、Jiafang He、Gui-Bai Liang、Carina P. Tan、Jin Cao、George J. Eiermann、Ling Xu、Gino Salituro、Andrew D. Howard、Sander G. Mills、Lihu Yang

  DOI：10.1016/j.bmcl.2011.03.114

  日期：2011.6

  The design, synthesis, and structure-activity relationship (SAR) for a series of beta-substituted 3-(4-aryloxyaryl) propanoic acid GPR40 agonists is described. Systematic replacement of the pendant aryloxy group led to identification of potent GPR40 agonists. In order to identify candidates suitable for in vivo validation of the target, serum shifted potency and pharmacokinetic properties were determined for several compounds. Finally, further profiling of compound 7 is presented, including demonstration of enhanced glucose tolerance in an in vivo mouse model. (C) 2011 Elsevier Ltd. All rights reserved.